Noninvasive Tools to Assess Hepatic Fibrosis: Ready for Prime Time?

Gastroenterology Clinics of North America

Volumn 40, Issue 3, 2011, Pages 507-521

  Schmeltzer, Paul A ^a   Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hepatic fibrosis; Liver biopsy; Noninvasive

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ELASTOGRAPHY; FIBROGENESIS; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PATIENT IDENTIFICATION; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING;

EID: 80052351718     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2011.06.010     Document Type: Review

References (52)

1. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001, 21:311-335.
2. Pinzani M., Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig and Liver Dis 2004, 36:231-242.
3. Moreira R.K. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007, 131:1728-1734.
4. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1665-1669.
5. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
6. Schuppan D., Afdhal N.H. Liver cirrhosis. Lancet 2008, 371:838-851.
7. Menghini G. One-second needle biopsy of the liver. Gastroenterology 1958, 35:190-199.
8. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of Liver. Hepatology 2000, 32:477-481.
9. Bedossa P. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
10. Mehta S.H., Lau B., Afdhal N.H., et al. Exceeding the limits of liver histology markers. J Hepatol 2009, 50:36-41.
11. Goodman Z.D. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007, 47:598-607.
12. Sheth S.G., Flamm S.L., Gordon F.D., et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998, 93:44-48.
13. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
14. Shaheen A.A., Myers R.P.Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis a systematic review. Hepatology 2007, 46:912-921.
15. Imbert-Bismut F., Ratziu V., Pieroni L., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
16. Poynard T., Imbert-Bismut F., Munteanu M., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comparative Hepatology 2004, 3:8.
17. Sebastiani G., Vario A., Guido M., et al. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007, 13:525-531.
18. Ratziu V., Massard J., Charlotte F., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:6.
19. Forns X., Ampurdanes S., Llovet J.M., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-992.
20. Adams L.A., Bulsara M., Rossi E., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51:1867-1873.
21. Sterling R.K., Lissen E., Clumeck N., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325.
22. Patel K., Gordon S.C., Jacobson I., et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004, 41:935-942.
23. Zaman A., Rosen H.R., Ingram K., et al. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007, 120. 280,e9-280.
24. Rosenberg W.M., Voelker M., Thiel R., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713.
25. Fontana R.J., Bonkovsky H.L., Naishadham D., et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009, 7:219-226.
26. Patel K., Benhamou Y., Yoshida E.M., et al. An independent and prospective comparison of two commercial fibrosi marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat 2009, 16:178-186.
27. Ngo Y., Munteanu M., Messous D., et al. A prospective analysis of the prognostic value of biomarkers (Fibrotest) in patients with chronic hepatitis C. Clin Chem 2006, 52:1887-1896.
28. Parkes J., Roderick P., Harris S., et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010, 59:1245-1251.
29. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008, 48:835-847.
30. Sandrin L., Fourquet B., Hasquenoph J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-1713.
31. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis c. Hepatology 2005, 41:48-54.
32. Castera L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
33. Talwalkar J.A., Kurtz D.M., Schoenleber S.J., et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007, 5:1214-1220.
34. Friedrich-Rust M., Ong M., Martens S., et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134:960-974.
35. Coco B., Oliveri F., Maina A.M., et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007, 14:360-369.
36. Yoneda M., Fujita K., Inamori M., et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007, 56;:1330-1331.
37. Corpechot C., El Naggar A., Poujol-Robert A., et al. assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006, 43:1118-1124.
38. Talwalkar J.A. Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology 2008, 135:299-302.
39. Castéra L., Foucher J., Bernard P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010, 51:828-835.
40. Talwalkar J.A., Yin M., Fidler J.L., et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008, 47:332-342.
41. Huwart L., Peeters F., Sinkus R., et al. Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomed 2006, 19:173-179.
42. Yin M., Talwalkar J.A., Glaser K.J., et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007, 5:1207-1213.
43. Huwart L., Sempoux C., Vicaut E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008, 135:32-40.
44. Friedrich-Rust M., Wunder K., Kriener S., et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009, 252:595-604.
45. Taouli B., Koh D.M. Diffusion-weighted mr imaging of the liver. Radiology 2010, 254:47-66.
46. Lim A.K., Patel N., Hamilton G., et al. The relationship of in vivo 31p mr spectroscopy to histology in chronic hepatitis C. Hepatology 2003, 37:788-794.
47. Carrion J.A., Navasa M.Bosch, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis c recurrence after liver transplantation. Liver Transpl 2006, 12:1791-1798.
48. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
49. Charlton M. Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there). Gastroenterology 2011, 140:25-28.
50. Roenigk H.H., Auerbach R., Maibach H., et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998, 478-485.
51. Laharie D., Zerbib F., Adhoute X., et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and noninvasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006, 23:1621-1628.
52. Berends M.A., Snoek J., de Jong E.M., et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: FibroTest predicts the presence and FibroScan predicts the absence of significant liver fibrosis. Liver Int 2007, 27:639-645.